The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease
Abstract
Background — Sympathetic tone is consistently raised in patients with end-stage renal disease (ESRD). We therefore tested the hypothesis that sympathetic activation is associated with mortality and cardiovascular events in a cohort of 228 patients undergoing chronic hemodialysis who did not have congestive heart failure at baseline and who had left ventricular ejection fraction >35%. Methods and Results — The plasma concentration of norepinephrine (NE) was used as a measure of sympathetic activity. Plasma NE exceeded the upper limit of the normal range (cutoff 3.54 nmol/L) in 102 dialysis patients (45%). In a multivariate Cox regression model that included all univariate predictors of death as well as the use of sympathicoplegic agents and β-blockers, plasma NE proved to be an independent predictor of this outcome (hazard ratio [1-nmol/L increase in plasma NE]: 1.07, 95% CI 1.01 to 1.14, P =0.03). Similarly, plasma NE emerged as an independent predictor of fatal and nonfatal cardiovascular events (hazard ratio [1-nmol/L increase in plasma NE] 1.08, 95% CI 1.02 to 1.15, P =0.01) in a model that included previous cardiovascular events, pulse pressure, age, diabetes, smoking, and use of sympathicoplegic agents and β-blockers. The adjusted relative risk for cardiovascular complications in patients with plasma NE >75th percentile was 1.92 (95% CI 1.20 to 3.07) times higher than in those below this threshold ( P =0.006). Conclusions — Sympathetic nerve overactivity is associated with mortality and cardiovascular outcomes in ESRD. Controlled trials with antiadrenergic drugs are needed to determine whether interference with the sympathetic system could reduce the high cardiovascular morbidity and mortality in dialysis patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ongoing systemic sympathetic activation has long been thought to be noxious, in heart failure 18,19 and renal failure.113”
From Obesity Paradox in Hypertension: Is This Because Sympathetic Activation in Obesity-Hypertension Takes a Benign Form? (2018) · cites this paper as [113]
In the citing paper
“A striking observation is that of Zoccali and colleagues, who demonstrated the plasma concentration of norepinephrine to predict the incidence of cardiovascular events, and survival, in patients with end-stage renal disease10.”
From The Sympathetic Nervous System Alterations in Human Hypertension (2015) · cites this paper as [10]
Citations
Cites
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Rozanski, A., Blumenthal, J. A., & Kaplan, J. (1999) · Circulation · doi:10.1161/01.cir.99.16.2192 · Cited by 2,846
Block, G. A., Hulbert‐Shearon, T. E., Nw, L., & Port, F. K. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v31.pm9531176 · Cited by 2,347
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Premature cardiovascular disease in chronic renal failure
Baigent, C., Burbury, K., & Wheeler, D. C. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02456-9 · Cited by 581
The prognostic importance of left ventricular geometry in uremic cardiomyopathy.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barré, P. E. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v5122024 · Cited by 480
Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage
Mancia, G., Grassi, G., Giannattasio, C., & Seravalle, G. (1999) · Hypertension · doi:10.1161/01.hyp.34.4.724 · Cited by 471
How to assess sympathetic activity in humans
Grassi, G., & Esler, M. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917060-00001 · Cited by 455
Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.
Foley, R. N., Parfrey, P. S., Harnett, J. D., Kent, G. M., Murray, D. C., & Barré, P. E. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v75728 · Cited by 415
Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure
Ligtenberg, G., Blankestijn, P. J., Oey, P. L., Klein, I. H. H. T., Dijkhorst-Oei, L.-T., Boomsma, F., Wieneke, G. H., van Huffelen, A. C., & Koomans, H. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401704 · Cited by 407
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 518
Hypertension in Hemodialysis Patients: An Opinion‐Based Update
Shafi, T., Waheed, S., & Zager, P. G. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12195 · Cited by 15
Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control
Zaheer, M., Chrysostomou, P., & Papademetriou, V. (2016) · Springer eBooks · doi:10.1007/978-3-319-39599-9_14 · Cited by 15
Delarue, J., Guillodo, M.-P., Guillerm, S., Elbaz, A., Marty, Y., & Clèdes, J. (2007) · British Journal Of Nutrition · doi:10.1017/s0007114507843534 · Cited by 15
Physiological Mechanisms of Hypertension and Cardiovascular Disease in End-Stage Kidney Disease
Clemmer, J. S., Shafi, T., & Obi, Y. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01203-7 · Cited by 16
Failure of Antihypertensive Treatment to Restore Normal Sympathetic Activity
Quarti‐Trevano, F., Seravalle, G., Facchetti, R., Tsioufis, K. P., Dimitriadis, K. S., Manta, E., Mancia, G., & Grassi, G. M. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24429 · Cited by 14
Potential role of endurance training in altering renal sympathetic nerve activity in CKD?
Howden, E. J., Lawley, J. S., Esler, M., & Levine, B. D. (2016) · Autonomic Neuroscience · doi:10.1016/j.autneu.2016.11.002 · Cited by 14
Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients
Zoccali, C., D’Arrigo, G., Leonardis, D., Pizzini, P., Postorino, M., Tripepi, G. L., & Mallamaci, F. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002030 · Cited by 14
Self-citationSimulating Lifetime Outcomes Associated with Complications for People with Type 1 Diabetes
Lung, T. W.-C., Clarke, P., Hayes, A., Stevens, R., & Farmer, A. A. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0047-4 · Cited by 14
Physical activity in sudden unexpected death in epilepsy: much more than a simple sport
Arida, R. M., Scorza, C. A., Schmidt, B., de Albuquerque, M., Cavalheiro, É. A., & Scorza, F. A. (2008) · Neuroscience Bulletin · doi:10.1007/s12264-008-0805-z · Cited by 14
McMahon, L. P. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16029.x · Cited by 15
Grassi, G. M. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000222748.37078.2d · Cited by 14
Manresa‐Rocamora, A., Sarabia, J. M., Guillén, S. P., Pérez-Berbel, P., Vicedo, B. M., Roche, E., Vicente-Salar, N., & Moya‐Ramón, M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191710463 · Cited by 16
Yano, Y., Hoshide, S., Etoh, T., Tamaki, N., Yokota, N., & Kario, K. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.05.031 · Cited by 13
Cardiac sympathetic dysautonomia in children with chronic kidney disease
Marino, V. S. P., Lima, E. M., Silva, J. M. P., de Sousa, M. R., & Ribeiro, A. L. P. (2008) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2008.01.003 · Cited by 13
Krum, H., Sobotka, P. A., Mahfoud, F., Esler, M., & Schlaich, M. P. (2011) · Cited by 13
Chronic Kidney Disease As a Potential Indication for Renal Denervation
Sanders, M. F., & Blankestijn, P. J. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00220 · Cited by 13
Rodriguez, B., Hochstrasser, A., Eugster, P. J., Grouzmann, E., Müri, R., & Z'Graggen, W. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.968725 · Cited by 10
Effects of Nondipping Blood Pressure Changes: A Nephrologist Prospect
Habas, E. M., Akbar, R. A., Alfitori, G. B., Farfar, K. L., Habas, E., Errayes, N., Habas, A., Adab, A. A., Rayani, A., Geryo, N., et al. (2023) · Cureus · doi:10.7759/cureus.42681 · Cited by 14
Effects of weight loss on renal function in overweight Japanese men
Masuo, K., Rakugi, H., Ogihara, T., Esler, M., & Lambert, G. W. (2011) · Hypertension Research · doi:10.1038/hr.2011.47 · Cited by 12
Kusuyama, T., Ogata, H., Takeshita, H., Kohno, H., Shimodozono, S., Iida, H., & Tsukazaki, T. (2014) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12168 · Cited by 12
Hoch, H., Stegbauer, J., Potthoff, S. A., Hein, L., Quack, I., Rump, L. C., & Vonend, O. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01223.x · Cited by 12
Target organ complications and prognostic significance of alerting reaction
Velasco, A., Ayers, C. R., Das, S. R., de Lemos, J. A., Khera, A., Victor, R. G., Kaplan, N. M., & Vongpatanasin, W. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000774 · Cited by 12
Hyperadrenergic and Labile Hypertension
Grassi, G. M., & Mancia, G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50061-1 · Cited by 12
Sakai, M., Tamura, K., Tanaka, Y., Tsurumi, Y., Okano, Y., Koide, Y., Endoh, T., Matsushita, K., Kihara, M., Hirawa, N., et al. (2005) · Clinical and Experimental Hypertension · doi:10.1081/ceh-200048738 · Cited by 12
Renal Denervation in End-Stage Renal Disease: Current Evidence and Perspectives
Scalise, F., Quarti‐Trevano, F., Toscano, E., Sorropago, A., Vanoli, J., & Grassi, G. M. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-023-00621-1 · Cited by 11
Measures of Effect in Epidemiological Research
Tripepi, G. L., Jager, K. J., Dekker, F. W., & Zoccali, C. (2010) · Nephron Clinical Practice · doi:10.1159/000312870 · Cited by 12
Self-citationStabilization of hypoxia inducible factor-1α ameliorates acute renal neurogenic hypertension
Koeners, M. P., Vink, E. E., Kuijper, A., Gadellaa, N., Rosenberger, C., Mathia, S., van den Meiracker, A. H., Garrelds, I. M., Blankestijn, P. J., & Joles, J. A. (2013) · Journal of Hypertension · doi:10.1097/hjh.0000000000000060 · Cited by 11
Конради, А. О. (2013) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2013-4-52-63 · Cited by 11
Testa, A., Mallamaci, F., Macrì, R., Pisano, A., Spoto, B., Malatino, L., Stancanelli, B., Tripepi, G. L., Benedetto, F. A., & Zoccali, C. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833bd21b · Cited by 10
Self-citationLimited reliability of heart rate as a sympathetic marker in chronic kidney disease
Dell’Oro, R., Quarti‐Trevano, F., Seravalle, G., Bertoli, S. V., Lovati, C., Mancia, G., & Grassi, G. M. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002763 · Cited by 10
Inampudi, C., Alvarez, P. A., Asleh, R., & Briasoulis, Α. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123164916 · Cited by 10
Sympathetic nervous system and arterial hypertension: new perspectives, new data
Hering, D., & Narkiewicz, K. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0089 · Cited by 10
Dialysis Patients and Critical Illness
Thompson, S., & Pannu, N. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.07.026 · Cited by 10
Sympathetic Hyperactivity—A Hidden Enemy in Chronic Kidney Disease Patients
Blankestijn, P. J. (2007) · Peritoneal Dialysis International · doi:10.1177/089686080702702s50 · Cited by 9
Pathophysiologie der Hypertonie: Was gibt es Neues?
Buchner, N. J., Vonend, O., & Rump, L. C. (2006) · Herz · doi:10.1007/s00059-006-2821-y · Cited by 10
Pathogenesis and treatment of hypertension in polycystic kidney disease
Neumann, J., Ligtenberg, G., Klein, I. H. H. T., & Blankestijn, P. J. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200209000-00007 · Cited by 10
Georgianos, P. I., Tziatzios, G., Roumeliotis, S. K., Vaios, V., Sgouropoulou, V., Tsalikakis, D., Liakopoulos, V., & Agarwal, R. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac253 · Cited by 10
Effects of Eprosartan in Chronic Kidney Disease
Blankestijn, P. J. (2006) · Journal of clinical and basic cardiology · Cited by 9
High blood pressure with elevated resting heart rate: a high risk “Sympathetic” clinical phenotype
Grassi, G. M., Dell’Oro, R., Bombelli, M., Cuspidi, C., & Quarti‐Trevano, F. (2023) · Hypertension Research · doi:10.1038/s41440-023-01394-9 · Cited by 9
Zoccali, C., & Mallamaci, F. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu029 · Cited by 9
Self-citationIm, H.-J., Kim, Y. J., Kim, H.-G., Kim, H.-S., & Son, C. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.12.049 · Cited by 9
Franczyk, B., Gluba-Brzózka, A., Bartnicki, P., & Rysz, J. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1506-1 · Cited by 9
Lubanda, J.-C., Chochola, M., Mlček, M., Neužil, P., Marek, J. J., Havránek, Š., Kuchynková, S., Fingrová, Z., Huang, K.-H. A., & Linhart, A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1319-0 · Cited by 9
Nishihara, M., Takesue, K., & Hirooka, Y. (2018) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2018.1465075 · Cited by 9
Wang, A. Y.-M., Li, P. K., Lui, S., & Sanderson, J. E. (2004) · Nephrology · doi:10.1111/j.1440-1797.2004.00260.x · Cited by 9
Relationship between serum parathyroid hormone and hypertension in hemodialysis patients.
Sedighi, O., Makhlough, A., Kashi, Z., & Zahedi, M. (2011) · Iranian Journal of Kidney Diseases · Cited by 9
Chrapko, B. E., Grzebalska, A. M., Nocuń, A., Książek, A., & Drop, A. (2014) · Nuclear Medicine Review · doi:10.5603/nmr.2014.0021 · Cited by 9
Effect of Icodextrin on Heart Rate Variability in Diabetic Patients on Peritoneal Dialysis
Orihuela, O., Ventura, M. D. J., Ávila–Díaz, M., Cisneros, A., Vicenté-Martı́nez, M., Furlong, M.-D.-C., García–González, Z., Villanueva, D., Alcántara, G., Lindholm, B., et al. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2012.00279 · Cited by 9
Assessment of ocular microcirculation in patients with end-stage kidney disease
Arimura, T., Shiba, T., Takahashi, M., Kumashiro, S., 長村洋徳, Matsumoto, T., Sakai, K., & Hori, Y. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-4137-z · Cited by 9
Campese, V. M. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328364d3f1 · Cited by 8
High Heart Rate, Sympathetic Overdrive, and Cardiovascular Risk in Hypertension
Grassi, G. M., Ram, C. V. S., & Palatini, P. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.09.022 · Cited by 8
Impact of Impaired Kidney Function on Arrhythmia-Promoting Cardiac Ion Channel Regulation
Sinha, F., Schweda, F., Maier, L. S., & Wagner, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814198 · Cited by 8
Y‐Hassan, S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.278 · Cited by 9
Renal Replacement Therapy in the End-Stage Renal Disease Patient with Critical Illness
Thompson, S., & Pannu, N. (2012) · Blood Purification · doi:10.1159/000341727 · Cited by 8
Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state
Dell’Oro, R., Trevano, F. Q., Gamba, P., Ciuffarella, C., Seravalle, G., Mancia, G., & Grassi, G. M. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001659 · Cited by 8
Chen, H.-H., Wu, C., Chen, Y., Tsai, C.-S., Lin, F.-J., & Yeh, H. (2006) · Coronary Artery Disease · doi:10.1097/01.mca.0000224418.21563.6e · Cited by 8
Determinants of hypertension-related cardiac organ damage: beyond the haemodynamic overload
Grassi, G. M. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000166833.25194.7b · Cited by 8
Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD)
Zoccali, C., Mallamaci, F., & Tripepi, G. L. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0022-x · Cited by 8
Self-citationIliakis, P., Dimitriadis, K. S., Tatakis, F., Vakka, A., Sakalidis, A., Pyrpyris, N., Fragoulis, C., Konstantinidis, D., Aznaouridis, K. A., & Tsioufis, K. P. (2025) · Biomedicines · doi:10.3390/biomedicines13081951 · Cited by 8
Gulalai, Ahmad, N., Wahid, A. H., Khan, A., Atif, M., & Khan, A. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00763-5 · Cited by 7
Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease
Seravalle, G., Quarti‐Trevano, F., Vanoli, J., Lovati, C., & Grassi, G. M. (2021) · Clinical Autonomic Research · doi:10.1007/s10286-021-00786-6 · Cited by 8
Autonomic Dysfunction and Inflammation in CKD
Zoccali, C., Mallamaci, F., Kanbay, M., Dounousi, E. C., Kotanko, P., Jankowski, J., & Chertow, G. M. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000591 · Cited by 7
Self-citationRenal denervation for resistant hypertension
Almeida, M., Gonçalves, P. D. A., de Oliveira, E. I., & Carvalho, H. C. (2015) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2014.07.011 · Cited by 8
Tsai, C., Lin, C., Ho, Y.-H., Lo, M., Liu, L.-Y. D., Lin, C., Huang, J., Peng, C., & Lin, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-33789-x · Cited by 7
Addressing the relationship between sympathetic activity and inflammation
Hausberg, M., Hillebrand, U., & Kisters, K. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328318efd4 · Cited by 7
Smoking, blood pressure and cardiovascular risk
Hausberg, M., Kosch, M., & Barenbrock, M. (2002) · Journal of Hypertension · doi:10.1097/00004872-200209000-00006 · Cited by 7
Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment
Edwards, N. C., Pavlovic, D., Ferro, C. J., & Townend, J. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01234-y · Cited by 6
Reliability of heart rate in reflecting cardiac sympathetic overdrive in type 2 diabetes mellitus
Dell’Oro, R., Quarti‐Trevano, F., Ciardullo, S., Perseghin, G., Mancia, G., & Grassi, G. M. (2024) · Clinical Autonomic Research · doi:10.1007/s10286-024-01054-z · Cited by 6
Young, B. E., Kissell, C. E., Vranish, J. R., Stephens, B. Y., Holwerda, S. W., & Fadel, P. J. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00337.2024 · Cited by 6
The Intuitive Case for β‐blockers in Patients with ESRD
McQuillan, R., & Chan, C. T. (2012) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2011.01016.x · Cited by 6
Inoue, T., Tokuyama, K., Yoshi, S., Nagayoshi, N., Iseki, C., & Iseki, K. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0641-3 · Cited by 6
Brain natriuretic peptide in acute myocardial infarction
Moltrasio, M., Cosentino, N., Metrio, M. D., Rubino, M., Cabiati, A., Milazzo, V., Discacciati, A., Marana, I., Bonomi, A., Veglia, F., et al. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000353 · Cited by 6
Musiałowska, D., & Małyszko, J. (2016) · Kardiologia Polska · doi:10.5603/kp.a2016.0095 · Cited by 6
Amami, K., Yamada, S., Yoshihisa, A., Kaneshiro, T., Hijioka, N., Nodera, M., Nehashi, T., & Takeishi, Y. (2021) · Annals of Noninvasive Electrocardiology · doi:10.1111/anec.12900 · Cited by 6
Depressive illness, the sympathetic nervous system and cardiac risk
Esler, M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328332d1d5 · Cited by 6
NEURAL, HORMONAL and RENAL INTERACTIONS IN LONG‐TERM BLOOD PRESSURE CONTROL
Evans, R. G., Malpas, S. C., Osborn, J. W., & Fink, G. D. (2005) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2005.04198.x · Cited by 6
Cardiovascular Disease in Chronic Kidney Disease
Stenvinkel, P., & Herzog, C. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00078-2 · Cited by 6
Heryć, R., Cecerska‐Heryć, E., Serwin, N. M., Stodolak, P., Goszka, M., Polikowska, A., Ciechanowski, K., & Wiśniewska, M. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04114-2 · Cited by 5
Sympathetic Responses to Antihypertensive Treatment Strategies
Dell’Oro, R., Quarti‐Trevano, F., Ambrosino, P., & Grassi, G. M. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01339-2 · Cited by 5
Boratyńska, M., Zoń, A. M., Obremska, M., Początek, K., Protasiewicz, M., Magott, M., & Klinger, M. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.10.051 · Cited by 5
Babu, G. G., Webber, M. R., Providencia, R. A., Kumar, S., Gopalamurugan, A. B., Rogers, D. P. S., Daw, H., Ahsan, S., Khan, F. Z., CHOW, A. W. C., et al. (2016) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.13080 · Cited by 5
Inaguma, D., Koide, S., Takahashi, K., Hayashi, H., Hasegawa, M., Yuzawa, Y., & AICOPP group (2017) · Nephrology · doi:10.1111/nep.13048 · Cited by 5
Barorezeptoraktivierungstherapie
Wallbach, M., Koziolek, M. J., & Wachter, R. (2018) · Der Internist · doi:10.1007/s00108-018-0488-0 · Cited by 5
Makimoto, H., Shimizu, K., Fujiu, K., Lin, T., Oshima, T., Amiya, E., Yamagata, K., Kojima, T., Daimon, M., Nagatomo, R., et al. (2018) · International Heart Journal · doi:10.1536/ihj.17-561 · Cited by 5
Chromogranin A pathway: from pathogenic molecule to renal disease
Mir, S. A., Biswas, N., Cheung, W., Wan, J., Webster, N. J. G., Macedo, E. M., O’Connor, D. T., & Vaingankar, S. M. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002295 · Cited by 5
Sata, Y., Burke, S. L., Eikelis, N., Watson, A. M. D., Gueguen, C., Jackson, K. L., Lambert, G. W., Lim, K., Denton, K. M., Schlaich, M. P., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17037 · Cited by 5
Renal denervation for resistant hypertension
Almeida, M., Gonçalves, P. D. A., de Oliveira, E. I., & Carvalho, H. C. (2015) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2014.07.009 · Cited by 5
Exercise training ameliorates adrenergic control in spontaneously hypertensive rats
Miranda, M., Lemos, M. D. P., Sasaki, J. E., da Mota, G. R., Marocolo, M., de Sordi, C. C., Almeida, T. R., da Silva, V. J. D., & Neto, O. B. (2020) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2020.1817474 · Cited by 5
Smoking and dialysis: A dreadful scenario for the cardiovascular system?
Orth, S. R., & Uehlinger, D. E. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00894.x · Cited by 5
Arterial Wave Reflection Is Elevated in Evening Hemodialysis Patients
Takenaka, T., Mimura, T., Kanno, Y., Ohno, Y., & Suzuki, H. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960802064542 · Cited by 5
End-Stage Renal Disease and Sudden Cardiac Death
Sakhuja, R., Shah, A. J., Hiremath, S. S., & Thakur, R. K. (2009) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2009.08.006 · Cited by 5
Masuo, K., & Lambert, G. W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2426 · Cited by 5
Małyszko, J., Koc‐Żórawska, E., Banach, M., & Myśliwiec, M. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283614638 · Cited by 5
Shiba, T., Sugiyama, T., Hori, Y., Matsumoto, T., Maeno, T., & Takahashi, M. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3145-5 · Cited by 4
Chrapko, B. E., Bednarek-Skublewska, A., ́kiewicz, G. S., & Książek, A. (2011) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32834df9ec · Cited by 4
Pro: Sympathetic renal denervation in hypertension and in chronic kidney disease
Blankestijn, P. J., Bots, M. L., Spiering, W., Leiner, T., & Voskuil, M. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu099 · Cited by 4
Ribeiro, L. R., de Oliveira, J. F., Orcy, R. B., Barros, C. C., Hense, J. D., dos Santos, F., Irigoyen, M. C., González, M. C., Oses, J. P., & Böhlke, M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00162.2018 · Cited by 4
Cardiac Injury, Maladaptation, and Heart Failure Incidence
Milks, M. W., & Nambi, V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00008-9 · Cited by 5
Norepinephrine, left ventricular disorders and volume excess in ESRD
ElHafeez, S. A., Tripepi, G. L., Stancanelli, B., Dounousi, E. C., Malatino, L., Mallamaci, F., & Zoccali, C. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0182-4 · Cited by 4
Self-citationWang, R., Hösl, K. M., Ammon, F., Markus, J., Koehn, J., Roy, S., Liu, M., Leal, C. D. R., Muresanu, D. F., Flanagan, S. R., et al. (2018) · Clinical Neurophysiology · doi:10.1016/j.clinph.2018.03.011 · Cited by 4
Metadata
- Authors
- Zoccali, C., Mallamaci, F., Parlongo, S., Cutrupi, S., Benedetto, F. A., Tripepi, G., Bonanno, G., Rapisarda, F., Fatuzzo, P., Seminara, G., Cataliotti, A., Stancanelli, B., & Malatino, L. S.
- Affiliations
- University of Catania (IT)
- ORCID
- Venue
- Circulation
- Published
- 2002-03-19
- Volume
- 105
- Issue
- 11
- Pages
- 1354-1359
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2166904705
- Cited by
- 519
- References
- 36
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 12 · 2023: 16 · 2022: 15 · 2021: 14 · 2020: 20 · 2019: 11 · 2018: 20 · 2017: 29 · 2016: 31 · 2015: 30 · 2014: 38 · 2013: 27 · 2012: 31
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Update notices
- correction (2002-05-07)
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regione Calabria
- Topics
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- plasma norepinephrine, end-stage renal disease, hemodialysis, sympathetic activation, cardiovascular mortality, cardiovascular events, beta-blockers, cardiovascular risk prediction
- MeSH terms
- Cardiovascular Diseases, Chronic Disease, Female, Renal Dialysis, Humans, Kidney Failure, Chronic, Male, Middle Aged, Norepinephrine, Predictive Value of Tests, Risk Factors, Stroke Volume, Sympathetic Nervous System, Cohort Studies, Comorbidity, Survival Rate, Proportional Hazards Models, Survival Analysis, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review